Home > Business > Guest Reports

Huons aims to gain ground in antiobesity drug market with new formulations

Published: 26 Feb. 2026, 09:27

The Huons building [HUONS]

Huons is expanding its presence in pharmaceuticals as it moves into the antiobesity treatment market with glucagon-like peptide-1 (GLP-1) drugs while advancing government-funded research and development to produce an oral formulation of semaglutide.

The company has bolstered its antiobesity treatment footprint with its flagship over-the-counter products S-Razine Tab. and Rosecana Cap., both formulated with naturally derived herbal ingredients.

S-Razine Tab. is based on a traditional herbal prescription specifically designed to reduce abdominal obesity, alleviate constipation and improve swelling by supporting the elimination of waste while restoring metabolic balance.

Rosecana Cap. contains green tea powder, which contributes to reducing body fat, increasing basal metabolic rate and promoting energy expenditure to maintain weight management.

Huons is currently advancing a government-funded project to develop an oral tablet formulation of semaglutide, the same active ingredient found in the Wegovy injectable, as part of a five-year initiative by the Ministry of Trade, Industry and Energy with a budget of 8.13 billion won ($5.6 million), with 6.3 billion won coming from the government.

On February 12, Huons filed a patent application for an oral formulation containing semaglutide distinct from Rybelsus, an oral treatment currently on the market.

The company conducted clinical trials that demonstrated improved bioavailability, weight loss and maintenance of hemoglobin A1c levels compared to existing products.

The patented technology aims to overcome the limitations of existing oral treatments. Upon registration, this patent will serve as the core intellectual property for a modified drug pipeline.

To secure future growth engines, Huons has been pursuing the development of antiobesity treatments based on GLP-1 receptor agonists, which are gaining traction for health management and diet functions by stimulating insulin secretion and inhibiting glucagon release to lower blood sugar, while simultaneously inducing satiety.

Huons got Investigational New Drug approval from the Ministry of Food and Drug Safety in December of last year for a Phase 1 clinical trial of HUC2-676, a low-molecular-weight synthetic peptide developed based on Novo Nordisk’s Saxenda injection. Huons is also conducting research on semaglutide as a low-molecular-weight synthetic peptide injectable, as the substance patent for the original semaglutide drug, Wegovy, is set to expire in August 2028.

BY LEE DAHYUN [[email protected]]

What is “Promoted Content”?

“Promoted Content” articles are written by our staff reporters. They are promoted to some extent by an external company.

Promoted Content is not the same as “Guest Reports,” which are paid advertorials.
Our reporters and editors retain complete editorial independence in the conception and production of Promoted Content.